# QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Source: https://onco.cc/trials/nct06786026/  
OnCo record `nct06786026` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab, iparomlimab and tuvonralimab and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC is a phase 2, interventional study registered as NCT06786026 by Fudan University, with a registry enrolment figure of 60 participants, started 2024-10-09 and due to reach its primary completion in 2025-09-30. Interventions recorded: bevacizumab; QL1706; Nab paclitaxel. Conditions listed: TNBC, Triple Negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06786026
- Phase: 2
- Setting: QL1706 Plus Nab-paclitaxel +/- Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: a Non-randomized, Multicenter Phase II Study
- Sponsor: Fudan University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06786026: https://clinicaltrials.gov/study/NCT06786026

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06786026.json